In the US, one key benefit of using data standards like CDISC in clinical research is that it enables faster regulatory review and approval of new drugs and treatments. The US FDA requires clinical trial data to be submitted using CDISC standards, which provide a common format that regulators can easily process and analyze. This streamlines the review process compared to non-standardized data submissions.